Binding of fusion protein FLSC IgG1 to CCR5 is enhanced by CCR5 antagonist Maraviroc

被引:5
|
作者
Latinovic, Olga [1 ,2 ]
Schneider, Kate [1 ,2 ]
Szmacinski, Henryk [3 ]
Lakowicz, Joseph R. [3 ]
Heredia, Alonso [1 ,4 ]
Redfield, Robert R. [1 ,4 ]
机构
[1] Univ Maryland, Sch Med, Inst Human Virol, Baltimore, MD 21201 USA
[2] Univ Maryland, Sch Med, Dept Microbiol & Immunol, Baltimore, MD 21201 USA
[3] Univ Maryland, Sch Med, Dept Biochem & Mol Biol, Baltimore, MD 21201 USA
[4] Univ Maryland, Sch Med, Dept Med, Baltimore, MD 21201 USA
关键词
HIV-1; CCR5; antagonist; Maraviroc; Fusion protein; HUMAN-IMMUNODEFICIENCY-VIRUS; HIV-1; CHEMOKINE; TYPE-1; EXPRESSION; ENTRY; ANTIBODY; CELLS; CD4; INFECTIONS;
D O I
10.1016/j.antiviral.2014.10.006
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The CCR5 chemokine receptor is crucial for human immunodeficiency virus type 1 (HIV-1) infection, acting as the principal coreceptor for HIV-1 entry and transmission and is thus an attractive target for antiviral therapy. Studies have suggested that CCR5 surface density and its conformational changes subsequent to virion engagement are rate limiting for entry, and consequently, infection. Not all CCR5 antibodies inhibit HIV-1 infection, suggesting a need for more potent reagents. Here we evaluated full length single chain (FLSC) IgG1, a novel IgG-CD4-gp12(BAL) fusion protein with several characteristics that make it an attractive candidate for treatment of HIV-1 infections, including bivalency and a potentially increased serum half-life over FLSC, the parental molecule. FLSC IgG1 binds two domains on CCR5, the N-terminus and the second extracellular loop, lowering the levels of available CCR5 viral attachment sites. Furthermore, FLSC IgG1 synergizes with Maraviroc (MVC), the only licensed CCR5 antagonist. In this study, we used both microscopy and functional assays to address the mechanistic aspects of the interactions of FLSC IgG1 and MVC in the context of CCR5 conformational changes and viral infection. We used a novel stochastic optical reconstruction microscopy (STORM), based on high resolution localization of photoswitchable dyes to visualize direct contacts between FLSC IgG1 and CCR5. We compared viral entry inhibition by FLSC IgG1 with that of other CCR5 blockers and showed FLSC IgG1 to be the most potent. We also showed that lower CCR5 surface densities in HIV-1 infected primary cells result in lower FLSC IgG1 EC50 values. In addition, CCR5 binding by FLSC IgG1, but not CCR5 Ab 2D7, was significantly increased when cells were treated with MVC, suggesting MVC allosterically increases exposure of the FLSC IgG1 binding site. These data have implications for future antiviral therapy development. (C) 2014 Elsevier B.V. All rights reserved.
引用
收藏
页码:80 / 90
页数:11
相关论文
共 50 条
  • [1] Binding of fusion protein FLSC IgG1 to CCR5 is enhanced by CCR5 antagonist Maraviroc
    Latinovic, Olga
    Szmacinski, Henryk
    Schneider, Kate
    Lakowicz, Joseph
    Heredia, Alonso
    Redfield, Robert
    JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2014, 67 : 82 - 82
  • [2] Maraviroc: a new CCR5 antagonist
    Sayana, Shilpa
    Khanlou, Homayoon
    EXPERT REVIEW OF ANTI-INFECTIVE THERAPY, 2009, 7 (01) : 9 - 19
  • [3] Treatment of HIV infection with the CCR5 antagonist maraviroc
    Kromdijk, Wiete
    Huitema, Alwin D. R.
    Mulder, Jan Willem
    EXPERT OPINION ON PHARMACOTHERAPY, 2010, 11 (07) : 1215 - 1223
  • [4] Maraviroc - The first CCR5 antagonist for the treatment of HIV
    Girotto, Jennifer E.
    FORMULARY, 2007, 42 (10) : 601 - 608
  • [5] Maraviroc - a CCR5 antagonist for the treatment of HIV-1 infection
    Van Der Ryst, Elna
    FRONTIERS IN IMMUNOLOGY, 2015, 6
  • [6] Maraviroc: A coreceptor CCR5 antagonist for management of HIV infection
    Yost, Raymond
    Pasquale, Timothy R.
    Sahloff, Eric G.
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2009, 66 (08) : 715 - 726
  • [7] Study of intracellular and immunomodulant effects of CCR5 Antagonist Maraviroc
    Sauzullo, I.
    Mengoni, F.
    Rossi, R.
    Celardo, I.
    Ghibelli, L.
    Lichtner, M.
    Massetti, A. P.
    Mastroianni, C. M.
    Vullo, V.
    INFECTION, 2010, 38 : 92 - 93
  • [8] Overcoming HERG affinity in the discovery of the CCR5 antagonist maraviroc
    Price, David A.
    Armour, Duncan
    de Groot, Marcel
    Leishman, Derek
    Napier, Carolyn
    Perros, Manos
    Stammen, Blanda L.
    Wood, Anthony
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2006, 16 (17) : 4633 - 4637
  • [9] Preparation and Activities of Macromolecule Conjugates of the CCR5 Antagonist Maraviroc
    Asano, Shigehiro
    Gavrilyuk, Julia
    Burton, Dennis R.
    Barbas, Carlos F., III
    ACS MEDICINAL CHEMISTRY LETTERS, 2014, 5 (02): : 133 - 137
  • [10] Pharmacotherapy of HIV-1 Infection: Focus on CCR5 Antagonist Maraviroc
    Latinovic, Olga
    Kuruppu, Janaki
    Davis, Charles
    Le, Nhut
    Heredia, Alonso
    CLINICAL MEDICINE INSIGHTS-THERAPEUTICS, 2009, 1 : 1497 - 1510